Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome

Human Reproduction

Volumn 19, Issue 3, 2004, Pages 534-539

  Guido, Maurizio ^a,b   Romualdi, D ^a   Suriano, R ^a   Giuliani, M ^a   Costantini, B ^a   Apa, R ^a,b   Lanzone, A ^b,c  

^a CATHOLIC UNIVERSITY   (Italy)

^b Istituto Scientifico Intl Paolo VI   (Italy)

^c OASI RESEARCH INSTITUTE IRCCS   (Italy)

Author keywords

Adrenal gland; Insulin; PCOS; Pioglitazone

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; CORTICOTROPIN; CYTOCHROME P450; GLUCOSE; HYDROXYPROGESTERONE; INSULIN; LUTEINIZING HORMONE; PIOGLITAZONE; STEROID 17,20 LYASE;

ADRENAL GLAND; ADULT; ARTICLE; BODY MASS; CLAMP; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DOSE RESPONSE; ECHOGRAPHY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; FEMALE; FOLLICULAR PHASE; HORMONE DETERMINATION; HORMONE RESPONSE; HUMAN; HYPERINSULINEMIA; INSULIN METABOLISM; INSULIN RESPONSE; INSULIN SENSITIVITY; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; STEROIDOGENESIS; TREATMENT OUTCOME;

EID: 1542502601     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/deh145     Document Type: Article

References (34)

1. Adams J, Polson DW and Abdulwahid N (1985) Multifollicular ovaries: Clinical and endocrine features and response to gonadotropin releasing hormone. Lancet 2,1375-1378.
2. Arlt W, Auchus RJ and Miller WL (2001) Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3β-hidroxysteroid dehydrogenase. J Biol Chem 276,16767-16771.
3. Arslanian SA, Lewy V, Danadian K and Saad R (2002) Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: Amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab 87,1555-1559.
4. Azziz R, Black V, Hines GA, Fox LM and Boots LR (1998) Adrenal androgen excess in the polycystic ovary syndrome: Sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis. J Clin Endocrinol Metab 83,2317-2323.
5. Azziz R, Ehrmann DA, Legro RS, Fereshetian AG, O'Keefe M and Ghazzi MN (2003) Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome. Fertil Steril 79,932-937.
6. Benjamin F, Deutsch S, Saperstein H and Seltzer VL (1996) Prevalence of the markers for the attenuated form of congenital adrenal hyperplasia and hyperprolactinemia masquerading as polycystic ovarian disease. Fertil Steril 46,215-221.
7. Bianchi P, Toscano V, Monaco G, Marano G, Lubrano C and Sciarpa F (1993) Effects of ACTH, insulin and insulin-like growth factor-I on guinea pig adrenals fasciculata-glomerulosa cells [Abstract]. Endocrinol Invest 16(Suppl 1),88.
8. Cara JF and Rosenfield R (1988) Insulin-like growth factor 1 and insulin potentiate luteinizing hormone induced androgen synthesis by rat ovarian thecal-interstitial cells. Endocrinology 123,733-739.
9. DeFronzo JP, Tobin JD and Andrei R (1979) Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol 237,E214-E223.
10. Ehrmann DA, Rosenfield RL, Barnes RB, Brigell DF and Sheikh Z (1992) Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med 327,157-162.
11. Fevold HR, Lorence MC, McCarthy JL, Trant JM, Kagimoto M, Waterman MR and Mason JL (1989) P450 17α from testis: Characterization of a full-length cDNA encoding a unique steroid hydroxilase capable of catalyzing both Δ4 and Δ5 steroid-17, 20-lyase reactions. Mol Endocrinol 3,968-975.
12. Fulghesu AM, Ciampelli M, Belosi C, Apa R, Pavone V and Lanzone A (2001) A new ultrasound criterion for the diagnosis of polycystic ovary syndrome: The ovarian stroma/total area ratio. Fertil Steril 76,326-331
13. Gillies PS and Dunn CJ (2000) Pioglitazone. Drugs 60,333-343.
14. Gonzalez F (1997) Adrenal involvement in polycystic ovary syndrome. Semin Reprod Endocrinol 15, 137-157.
15. Homburg R (2002) What is polycystic ovarian syndrome? A proposal for a consensus on the definition and diagnosis of polycystic ovarian syndrome. Hum Reprod 17,2495-2499.
16. Horrocks PM, Franks S, Hockley AD, Rolfe EB, Van Noorden S and London DR (1982) An ACTH secreting pituitary tumor arising in a patient with congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 17,457-468.
17. Horrocks PM, Kandeel FR, London DR, Butt WR, Lynch SS and Holder G (1983) ACTH function in women with polycystic ovarian syndrome. Clin Endocrinol 19,143-150.
18. Kase N, Kowal J, Perloff W and Soffer LG (1963) In vitro production of androgens by a virilizing adrenal adenoma and associated polycystic ovaries. Acta Endocrinol (Copenh) 44,15-19.
19. LaMarca A, Morgante G, Paglia T, Ciotta L, Cianci A and De Leo V (1999) Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome. Fertil Steril 72,985-989
20. Lanzone A, Fulghesu AM, Guido M, Caruso A and Mancuso S (1992) Differential androgen response to adrenocorticotropic hormone stimulation in polycystic ovarian syndrome: Relationship with insulin secretion. Fertil Steril 58,296-301.
21. Lanzone A, Fulghesu AM, Guido M, Ciampelli M, Caruso A and Mancuso S (1994) Differential androgen response to adrenocorticotrophin hormone stimulation and effect of opioid antagonist on insulin secretion in polycystic ovarian syndrome. Hum Reprod 9,2242-2246.
22. Lazar L, Kauli R, Bruchis C, Nordemberg J, Galatzer A and Pertzelan A (1995) Early polycystic ovary-like syndrome in girls with central precocious puberty and exaggerated adrenal response. Eur J Endocrinol 133,403-406.
23. Lehmann J, Moore L, Smith-Oliver T, Wilkinson W, Wilson T and Kliewer S (1995) An antidiabetic thiazolidindiones is a high affinity ligand for peroxisome proliferator-activated receptor (PPAR). J Biol Chem 270,12953-12956.
24. Lucky AW, Rosenfield RL, McGuire S, Rudy S and Helke S (1986) Adrenal androgen hyperresponsiveness to adrenocorticotropin in women with acne and/or hirsutism: Adrenal enzyme defects and exaggerated adrenarche. J Clin Endocrinol Metab 62,840-48.
25. Meikle AW, Worley RJ and West CD (1984) Adrenal corticoid hyperresponsiveness in hirsute women. Fertil Steril 41,575-579.
26. Miller WL (1988) Molecular biology of steroid hormone synthesis. Endocr Rev 9,295-318.
27. Moghetti P, Castello R, Negri C, Tosi F, Spiazzi GG, Brun E, Calducci R, Toscano V and Muggeo M (1996) Insulin infusion amplifies 17α-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: Apparent relative impairment of 17, 20-lyase activity. J Clin Endocrinol Metab 81,881-886.
28. Moran C and Azziz R (2001) The role of the adrenal cortex in polycystic ovary syndrome. Obstet Gynecol Clin North Am 28,63-75.
29. National Diabetes Data Group (1979) Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28,1039-1057.
30. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN and Blackard WG (1991) A direct effect of hyperinsulinemia on serum sex-hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 72,83-89.
31. New MI, Lorentzen F, Lerner AJ, Kohn B, Oberfeld SE, Pollack MS, Du Pont B, Stoner L, Levy DJ, Pang S and Levin LS (1983) Genotyping steroid 21-hydroxylase deficiency: Hormonal reference data. J Clin Endocrinol Metab 57,320-326.
32. Romualdi D, Guido M, Ciampelli M, Giuliani M, Leoni F, Perri C and Lanzone A (2003) Selective effects of pioglitazone on insulin and androgen abnormalities in normo and hyperinsulinemic obese patients with polycystic ovary syndrome. Hum Reprod 18,1210-1219.
33. Rosenfield RL, Barnes RB, Cara JF and Lucky AW (1990) Dysregulation of cytochrome P450c17α as the cause of polycystic ovary syndrome. Fertil Steril 53,785-791.
34. Roy S, Mahesh VB and Greenblatt RB (1962) Effect of dehydroepiandrosterone and androstenedione on the reproductive organs of rats: Production of cystic changes in the ovary. Nature 68,42-43.